Ikarovec at ESGCT 2026

Oct 27–30, 2026 Hamburg, Germany ~2.5k attendees Website

Ikarovec brings 2 presentations to ESGCT 2026 in Hamburg. Its work centres on AAV gene therapy for chronic eye disease that delivers two proteins acting on separate pathways. Topics include preclinical and manufacturing development of a candidate for geographic atrophy and upstream process work for bicistronic AAV.

OrganizationESGCT 2026 Attendance
Ikarovec
Norwich, UK
ikarovec.com
Biotech
Develops bicistronic AAV gene therapies for chronic eye diseases, delivering two proteins acting on different disease pathways; lead target is age-related macular degeneration.
Poster
Wed Oct 28
1:30pm–3:30pm
Preclinical and Manufacturing Development of Bicistronic Dual-Pathway Gene Therapies to Treat AMD: Focus on IKAR-001 for Geographic Atrophy (GA)
AAVs / non integrative vectors
Poster
Thu Oct 29
2:00pm–4:00pm
Upstream Optimization Strategies for High-Quality Bicistronic AAV Manufacturing
Manufacturing

Explore the full ESGCT 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Hamburg. Leave your work email and we’ll be in touch.

Privacy

Download the full ESGCT 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Ikarovec

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the European Society of Gene & Cell Therapy. Submit a correction